UNSPSC 51294521: Paroxetine hydrochloride hydrate

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula 2C19H20FNO3.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X2ELS050D8, chemically known as (-)-(3s,4r)-4-(p-fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)-methyl)piperidine hydrochloride hemihydrate, but more generally known as paroxetine hydrochloride hydrate, which bears US NIH Compound Identifier 5282487.

European Medicines Agency schedules paroxetine hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09631MIG. Most nations, for tariff purposes, schedule paroxetine hydrochloride hydrate under HS 29349990. SMILES: C1CC(CCC1[C@@H]2CCNC[C@H]2COC3CCC4C(C3)OCO4)F.C1CC(CCC1[C@@H]2CCNC[C@H]2COC3CCC4C(C3)OCO4)F.O.CL.CL.

UNSPSC 51294521 Paroxetine hydrochloride hydrate is a Commodity code that nominally designates a specific antidepressant pharmaceutical; however, recent state and local solicitations tagged with this code show little alignment with paroxetine itself and instead reflect broader pharmaceutical procurement — generic multi-source drugs, over-the-counter products, naloxone and drug deactivation systems, and direct-to-manufacturer prescription programs. State and local governments appear to use this code as a catch-all pharmaceutical classification rather than a precise product line. Issuing bodies span state health agencies, county health departments, and multistate cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, has been particularly active, soliciting generic pharmaceuticals and OTC products through cooperative contracts. Texas Health and Human Services Commission and Seminole County, Florida also issued pharmaceutical-related procurements under or near this code in the past quarter.

Geographic activity concentrates in Minnesota (through MMCAP's multistate vehicle covering participating state and local government facilities, including Oregon), Texas, and Florida. Recent solicitations include MMCAP's Request for Proposal for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, with questions closed February 18, 2026), which required vendors to supply through authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification; Seminole County's Invitation for Bid (IFB 60459723LAS) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida (due July 26, 2023); and Texas HHS's Request for Information on direct-to-manufacturer prescription programs (due April 3, 2026), which seeks vendor capabilities for establishing direct relationships between state pharmacy benefit programs and manufacturers outside traditional PBM and wholesaler channels. Vendors pursuing this code should verify actual product scope in each solicitation, as the nominal code designation does not reliably predict what is being purchased.